ABCSG 47 / IMpassion030 Summary

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

Start: 07/2019
Coordinating Investigator: Günther Steger, Vienna
Sample size: 2300 (international)
Design:
(Click to enlarge)
ABCSG 47 / IMpassion030